DelveInsight’s “Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Anemia In Chronic Kidney Disease Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Anemia In Chronic Kidney Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Anemia In Chronic Kidney Disease: An Overview
Anemia is a frequent complication of chronic kidney disease (CKD) and is associated with a decrease in patients’ quality of life, causing an increase in morbidity and mortality. It is also believed to accelerate the rate of progression of CKD. Anemia in chronic kidney disease is typically attributed to the decrease of erythropoietin production that accompanies the fall in the Glomerular filtration rate (GFR).
According to the National Institute of Diabetes and Digestive and Kidney Diseases, Anemia commonly occurs in people with chronic kidney disease (CKD)—the permanent, partial loss of kidney function. Anemia might begin to develop in the early stages of CKD, where only 20 to 50 percent of normal kidney function is restored. Anemia tends to worsen as CKD progresses. Most people with total loss of kidney function or kidney failure have anemia.
Anemia In Chronic Kidney Disease Market Key Facts
-
According to the study conducted by Steven F. et al. (2018), in patients with stage 3 CKD, 22.2% of patients with diabetes were anemic, increasing to 52.4% in stage 4 CKD.
-
At least 90% of patients who end up on dialysis will eventually develop anemia of chronic disease.
-
The prevalence of anemia is high (47.7%) in patients with nondialysis CKD and increases as CKD progresses, being present in approximately 42% of patients with stage 3 CKD, increasing to approximately 76% in stage 5 CKD.
Anemia In Chronic Kidney Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Anemia In Chronic Kidney Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Anemia In Chronic Kidney Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Anemia In Chronic Kidney Disease Epidemiology
According to the NIDDK, Anemia commonly occurs in people with chronic kidney disease (CKD), which results in permanent, partial loss of kidney function. Anemia might begin to develop in the early stages of CKD when someone has 20 to 50 percent of normal kidney function. Anemia tends to worsen as CKD progresses. Most people with total loss of kidney function or kidney failure have anemia.
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Anemia In Chronic Kidney Disease Epidemiology Segmentation
-
Total Prevalent Cases of Chronic Kidney Disease
-
Total Prevalent Cases of Anemia in Chronic Kidney Disease
-
Diagnosed and Treatable Population of Anemia in Chronic Kidney Disease
-
Age-specific Prevalent Cases of Anemia in Chronic Kidney Disease
-
Total Prevalent Cases of Anemia in different stages of Chronic Kidney Disease
Anemia In Chronic Kidney Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anemia In Chronic Kidney Disease market or expected to get launched during the study period. The analysis covers Anemia In Chronic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Anemia In Chronic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Anemia In Chronic Kidney Disease Market Will Evolve by 2032 @
https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-market
Anemia In Chronic Kidney Disease Therapeutics Analysis
Currently, the treatment paradigm for Anemia in Chronic Kidney Disease involves the use of Iron therapies, Erythropoietin stimulating agent (ESA) therapies, Red Blood Transfusions, Vitamin B12 & Folic Acid Supplements, and nutrition.
The development of recombinant human erythropoietin (rhEpo) as a therapeutic modality has changed the management of anemia in CKD. Novel therapeutic approaches, technological advancements, and an increase in government support are expected to be responsible for the growth of the therapeutics market in the coming years.
To further improve the treatment scenario, globally, some of the key companies are actively working in the Anemia In Chronic Kidney Disease Therapeutics Market.
Some of the key companies in the Anemia In Chronic Kidney Disease Market include:
-
FibroGen
-
Akebia Therapeutics
-
GlaxoSmithKline
-
Astellas Pharma
And many others
Anemia In Chronic Kidney Disease Therapies covered in the report includes:
-
Evrenzo
-
Vadadustat
-
Daprodustat
And many others.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Anemia In Chronic Kidney Disease Competitive Intelligence Analysis
4. Anemia In Chronic Kidney Disease Market Overview at a Glance
5. Anemia In Chronic Kidney Disease Disease Background and Overview
6. Anemia In Chronic Kidney Disease Patient Journey
7. Anemia In Chronic Kidney Disease Epidemiology and Patient Population (In US, EU5, and Japan)
8. Anemia In Chronic Kidney Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Anemia In Chronic Kidney Disease Unmet Needs
10. Key Endpoints of Anemia In Chronic Kidney Disease Treatment
11. Anemia In Chronic Kidney Disease Marketed Products
12. Anemia In Chronic Kidney Disease Emerging Drugs and Latest Therapeutic Advances
13. Anemia In Chronic Kidney Disease Seven Major Market Analysis
14. Attribute Analysis
15. Anemia In Chronic Kidney Disease Market Outlook (In US, EU5, and Japan)
16. Anemia In Chronic Kidney Disease Access and Reimbursement Overview
17. KOL Views on the Anemia In Chronic Kidney Disease Market
18. Anemia In Chronic Kidney Disease Market Drivers
19. Anemia In Chronic Kidney Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Cardiac Valvulotome Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for the Cardiac Valvulotome. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Cardiac Valvulotome market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/